More

    COVID Vaccines

    spot_img

    iNCOVACC: Bharat Biotech Reveals World’s 1st Nasal COVID Vaccine Price

    Bharat Biotech, a global leader in vaccine innovation and developer of vaccines for infectious diseases has dedicated iNCOVACC® (BBV154) to the nation, world’s 1st COVID intranasal vaccine for Primary series and Heterologous booster. iNCOVACC® is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine candidate was evaluated in phase I, II and III clinical trials with successful results. Product development and...

    Bharat Biotech iNCOVACC Vaccine priced ₹800 in CoWIN, ₹325 for the Govt Supplies, Rollout in January 2023

    Hyderabad, Dec 27, 2022: Bharat Biotech iNCOVACC® (BBV154),the nasal vaccine for covid-19 is scheduled to be introduced in the country as a booster dose shortly. iNCOVACC® is now available on CoWin, and priced at INR 800 for private markets and priced at INR 325 for supplies to Govt of India and State Governments. The price is exclusive of GST. Earlier this month, Bharat Biotech received...

    Bharat Biotech Nasal Vaccine as Covid Booster Dose, First in Hospitals: Govt

    Indians' will soon have access to Bharat Biotech's covid-19 nasal vaccine "iNCOVACC" . Health Minister Dr Mansukh Mandaviya said that Bharat biotech nasal vaccine has been approved and will soon be added in CoWIN app. The Covid-19 vaccine has received the approval for use as a booster dose -Dr Mansukh Mandaviya said. Bharat Biotech's intranasal Covid vaccine will be available in private centres and will...

    iNCOVACC Fast Facts: World’s first Intranasal vaccine approved by India

    Bharat Biotech iNCOVACC®️ (BBV154), has received approval from the Central Drugs Standard Control Organisation (CDSCO) under Restricted Use in Emergency Situation for ages 18 and above, in India, for heterologous booster doses. In heterologous boosting, a person administered a different vaccine from the one that was used for the primary dose series. Key Facts about iNCOVACC Vaccine iNCOVACC®️ is the world’s first Intranasal vaccine for COVID to...

    Nations are destroying Millions of Moderna Covid19 Vaccines

    9 million doses of Moderna will be disposed of in Switzerland (MRNA.O) The government announced  that 5.1 million doses of COVID-19 vaccine that have passed their expiration date will follow suit by February. The wastage is a result of Switzerland's decision to acquire more vaccines than was necessary to ensure that its population of 8.7 million people would have access to enough doses even...

    World’s 1st intra nasal vaccine iNCOVACC by Bharat Biotech approved for emergency use

    Bharat Biotech's intra nasal vaccine iNCOVACC (BBV154), has received approval under Restricted Use in Emergency Situation for ages 18 and above in India. This is World's First Intranasal Vaccines to receive approvals for Primary 2 dose schedule . Highlights of Bharat Biotech Intra Nasal Vaccine - iNCOVACC iNCOVACC receives approval under Restricted Use in Emergency Situations for ages 18 and above.Bharat Biotech is a global leader in...

    Moderna sues Pfizer and BioNTech for violating the Covid19 vaccine patent

    On Friday, mRNA vaccine developer Moderna filed a patent infringement lawsuit against Pfizer and its German partner BioNTech over the development of the first COVID-19 vaccine approved in the United States, claiming that the defendants stole technology that Moderna had developed years before the pandemic. Moderna in a tweet wrote, Moderna is filing the suit against Pfizer and BioNTech, alleging infringement of patents central to Moderna’s...

    Intranasal Covid vaccine BBV154 is safe, regulators approvals awaited: Bharat Biotech

    In controlled clinical trials for the Covid vaccine BBV154 as a primary and as a heterologous booster, Bharat Biotech International Limited (BBIL) said today, its intranasal Covid-19 vaccine BBV154 has demonstrated to be safe, well-tolerated, and immunogenic in subjects. BBIL has submitted the data from both the Phase III trials for approval to India's regulatory authorities. BBV154 is a recombinant replication-deficient adenovirus vectored vaccine with...

    Japan Approves COVAXIN booster dose for Travelers; reinforces the effectiveness of Universal Covid Vaccine

    Japan on Friday accorded approval for Bharat Biotech's Covaxin booster dose for travellers. In April this year, the nation included the Made-in-India Covid-19 vaccine in the list of recognised vaccines. And, now (August 5), Japan has also approved the booster shot of Covaxin. Bharat Biotech wrote in a statement, "We are proud to announce, Japan has approved COVAXIN booster dose for travellers". Earlier this month, the...

    New Peer Review Proves COVAXIN Booster Dose Provides Multiple Benefits

    According to a new peer-reviewed study, administration of Bharat Biotech's COVAXIN Booster (3rd dose), after 6 months of two dose vaccination, dramatically increased neutralizing antibody responses against both homologous and heterologous strains (Alpha, Beta, Delta, Delta Plus and Omicron) and showed increased memory B cell response. According to the latest peer review study published in Nature, COVAXIN, its whole-virion inactivated COVID-19 vaccine, has proven to...

    Latest Updates